2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W015820R
    Phthalide (Standard) 87-41-2
    Phthalide (Standard) is an analytical standard of Phthalide. This product is intended for research and analytical applications. Phthalide is a chemical scaffold. Phthalide can be used to synthesize a variety of phthalate derivatives, including anti-inflammatory agents, antimicrobial agents, antioxidants and blood-tumor barrier regulators.
    Phthalide (Standard)
  • HY-W016823R
    Tyramine hydrochloride (Standard) 60-19-5
    Tyramine (hydrochloride) (Standard) is the analytical standard of Tyramine (hydrochloride). This product is intended for research and analytical applications. Tyramine hydrochloride is an amino acid that helps regulate blood pressure. Tyramine hydrochloride occurs naturally in the body, and it's found in certain foods.
    Tyramine hydrochloride (Standard)
  • HY-W017540S
    Cyclocreatine-13C3 98%
    Cyclocreatine-13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer.
    Cyclocreatine-13C3
  • HY-W036034A
    GRK-IN-1 5423-98-3 98%
    GRK-IN-1 is a potential G protein-coupled receptor kinase (GRK) inhibitor.
    GRK-IN-1
  • HY-W050000R
    OR-1855 (Standard) 101328-85-2
    Tanshinone IIA sulfonate (sodium) (Standard) is the analytical standard of Tanshinone IIA sulfonate (sodium). This product is intended for research and analytical applications. Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
    OR-1855 (Standard)
  • HY-W094475D
    Magnesium sulfate heptahydrate, meets analytical specification of Ph. Eur. BP USP FCC 10034-99-8 98%
    Magnesium sulfate heptahydrate, meets analytical specification of Ph. Eur. BP USP FCC is currently the anticonvulsant of choice for the prevention and control of eclamptic fits. Magnesium sulfate is also widely used as a tocolytic agent.
    Magnesium sulfate heptahydrate, meets analytical specification of Ph. Eur. BP USP FCC
  • HY-W110242A
    (S)-CPP sodium 194979-70-9 98%
    (S)-CPP sodium serves as an inhibitor of the branched-chain α-ketoacid dehydrogenase complex (BCKDC) kinase, commonly referred to as BDK or keto acid dehydrogenase kinase. As a negative regulator of BCKDC activity, the inhibition of BDK by (S)-CPP (with an IC50 of 6.3 μM) results in the activation of the complex and a notable decrease in plasma levels of leucine/isoleucine and valine in wild-type mice.
    (S)-CPP sodium
  • HY-W127530R
    α-Tocopherol phosphate disodium (Standard) 60934-46-5
    α-Tocopherol phosphate (Standard) (alpha-Tocopherol phosphate (Standard)) disodium is the analytical standard of α-Tocopherol phosphate disodium (HY-W127530). This product is intended for research and analytical applications. α-Tocopherol phosphate disodium is an antioxidant that protects against long-wave UVA1 induced cell death and scavenge UVA1 induced ROS in a skin cell model. α-Tocopherol phosphate disodium exhibits angiogenesis-promoting activity.
    α-Tocopherol phosphate disodium (Standard)
  • HY-116790BSA
    (±)-Penbutolol-d9 hydrochloride 1346605-01-3 98%
    (±)-Penbutolol-d9 (hydrochloride) is a deuterium labeled (±)-Penbutolol hydrochloride. (+)-Penbutolol hydrochloride is a β-adrenoceptor antagonist, with an IC50 of 0.74 μM.
    (±)-Penbutolol-d9 hydrochloride
  • HY-119695AS1
    Simvastatin acid-d9 ammonium 98%
    Simvastatin acid-d9 ammonium is deuterated labeled Simvastatin acid ammonium (HY-119695A). Simvastatin acid (Tenivastatin) ammonium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.
    Simvastatin acid-d9 ammonium
  • HY-W002112S1
    (±)-Nornicotine-d7 98%
    (±)-Nornicotine-d7 is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia.
    (±)-Nornicotine-d7
  • HY-W013812S2
    Ethyl linoleate-d2 1404475-07-5 98%
    Ethyl linoleate-d2 (Linoleic Acid ethyl ester-d2; Mandenol-d2) is the deuterium labeled Ethyl linoleate (HY-W013812). Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators.
    Ethyl linoleate-d2
  • HY-W013812S3
    Ethyl linoleate-d11 98%
    Ethyl linoleate-d11 (Linoleic Acid ethyl ester-d11) is deuterium labeled Ethyl linoleate. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators.
    Ethyl linoleate-d11
  • HY-10271
    Flovagatran sodium 871575-98-3 98%
    Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis.
    Flovagatran sodium
  • HY-10275
    Atecegatran 433937-74-7 98%
    Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders.
    Atecegatran
  • HY-10281
    YM-60828 methanesulfonate 209187-02-0 98%
    YM-60828 is an FXa inhibitor with antithrombotic properties. In the rat arteriovenous shunt model, YM-60828 does not prolong coagulation time but reduces the levels of thrombin-antithrombin III complex (TAT) in a dose-dependent manner. YM-60828 exhibits only anti-FXa activity and does not show anti-thrombin activity, indicating that its antithrombotic effect is independent of thrombin. Therefore, the antithrombotic effect of YM-60828 can be monitored by TAT.
    YM-60828 methanesulfonate
  • HY-10306
    Gantofiban 183547-57-1 98%
    Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect.
    Gantofiban
  • HY-10658
    AC-7954 477313-09-0 98%
    AC-7954 is a selective nonpeptidic urotensin receptor agonist (EC50: 300 nM at the human UII receptor).
    AC-7954
  • HY-10666
    SB-436811 346729-66-6 98%
    SB-436811 is a human urotensin-II receptor antagonist with a pKi value of 6.7.
    SB-436811
  • HY-10725
    Tanogitran 637328-69-9 98%
    Tanogitran is a dual inhibitor targeting Factor Xa and thrombin (thrombin), with Ki values of 26 and 2.7 nM, respectively. Tanogitran exhibits anticoagulant activity and can be used for research in thrombotic diseases.
    Tanogitran
Cat. No. Product Name / Synonyms Application Reactivity